Asahi Kasei Pharma gains Japanese rights to zoledronic acid for osteoporosis
This article was originally published in Scrip
Executive Summary
Asahi Kasei Pharma has licensed from Novartis the exclusive rights to develop and market zoledronic acid in Japan for the treatment of osteoporosis.